Team:Warwick/Human/Changes

From 2014.igem.org

(Difference between revisions)
 
(35 intermediate revisions not shown)
Line 37: Line 37:
         <!--CONTENT START-->
         <!--CONTENT START-->
 +
       
 +
<a href="https://2014.igem.org/Main_Page"> <img class = "headerImage" style = "width: 12%;"
 +
src="https://static.igem.org/mediawiki/2014/2/22/Logo2014v2.png"> </a>
          
          
         <a href="/Team:Warwick"> <img class = "headerImage" style = "width: 30%;" src="https://static.igem.org/mediawiki/2014/f/ff/RepliconLogoON.png"> </a>
         <a href="/Team:Warwick"> <img class = "headerImage" style = "width: 30%;" src="https://static.igem.org/mediawiki/2014/f/ff/RepliconLogoON.png"> </a>
-
         <!--<a href="/Team:Warwick/DMB">--><a href="/Team:Warwick"> <img class = "headerImage" style = "width: 12%;"  
+
         <a href="/Team:Warwick"> <img class = "headerImage" style = "width: 12%;"  
src="https://static.igem.org/mediawiki/2014/f/f6/Warwick_logo.png"> </a>
src="https://static.igem.org/mediawiki/2014/f/f6/Warwick_logo.png"> </a>
Line 53: Line 56:
             <li> <a href = "/Team:Warwick/Interlab"> INTERLAB </a> </li>
             <li> <a href = "/Team:Warwick/Interlab"> INTERLAB </a> </li>
             <li> <a href = "/Team:Warwick/Attributions"> ATTRIBUTIONS </a> </li>
             <li> <a href = "/Team:Warwick/Attributions"> ATTRIBUTIONS </a> </li>
-
             <li> <a href = "/Team:Warwick/Judging"> JUDGING </a> </li>
+
              
         </div>
         </div>
Line 67: Line 70:
             <div id = "pageContent">
             <div id = "pageContent">
             <!-- THIS IS WHERE YOUR MAIN BODY GOES -->
             <!-- THIS IS WHERE YOUR MAIN BODY GOES -->
-
            </div>
+
 
 +
 
 +
 
 +
<h1>Project Specific Changes</h1> <br> </br>
 +
<p>As part of the project we looked to spread synthetic biology throughout the community. We approached this feat through several different avenues.</p>
 +
<br> </br>
 +
<p>Our project came into fruition after extensive debate and discussion, the idea of introducing a mechanism by which RNA can be propagated is both conceptually and theoretically appealing. Using our replicon system to target production of a siRNA directed against a target (DPP-IV) shows just one of many applications that our system holds.
 +
Initially, it was not so straight forward when considering additional elements that we might require – for safety of the system was not on our minds. However, after due deliberation we decided to embark and ask questions and most importantly, seek answers.
 +
We started small and simple, with the obvious question on how people perceive our system? </p>
 +
 
 +
<p>We decided to conduct a Q + A session, in which academics, students and the wider public were in attendance. Whilst lots of interesting questions were raised, we collectively became stuck when faced with the following question: </p>
 +
 
 +
<br> <p> <b>What have you done to ensure your system is safe?</b>  <br>
 +
 
 +
Having reflected on this question, we realized that we failed to consider how our system would be safe - as one of the main applications of our system was to help treat Diabetes, we had to re-think and go back to the drawing board. We came up with two ideas which we feel will greatly improve the safety, but also the efficiency of our system </p>
 +
 
 +
<br> <p> <ins>Aptazyme </ins>
 +
 
 +
<br> We decided to use a theophylline induced aptazyme, this essentially acts as a kill-switch if our system becomes unstable - it is possible to cleave our siRNA transcript and prevent our system from functioning. A general descriptor for the Aptazyme is below:
 +
 
 +
<br> An aptazyme is an RNA based switch that operates by ribozyme-mediated cleavage of RNA. This part derives from Hartig et al., 2002 and requires the addition of theophylline to induce hammerhead ribozyme activation and cleavage, as depicted in Figure 1a. The part sequence is modified to contain a stop codon at the end, as an RBS is present.  </p>
 +
 
 +
<p style="float:none;clear:both; align="center"><center>
 +
<img style="width:70%;" align="middle" src="https://static.igem.org/mediawiki/2014/b/b5/Aptazyme.png " width="500" height="400"></center><br>
 +
</p>
 +
<!--<p><center> <img class = "floatright" src="https://static.igem.org/mediawiki/2014/b/b5/Aptazyme.png " width="500" height="400" align="left" > </center></p> -->
 +
 
 +
<br> <p> <ins>MS2 </ins><br>In addition, we introduced another safety device, essentially this would rate limit the level of RNA dependent RNA polymerase (RdRp) production. Our design of RNA dependent RNA polymerase essentially incorporated an MS2 bacteriophage coat protein, linked via a P2A linker protein. A general descriptor for the part we used is below:
 +
MS2 bacteriophage coat protein part derives from Fussenegger et al., 2012. The MS2 coat protein binds a specific stem-loop structure, referred to as the MS2 box. This acts as a silencing mechanism of RNA through translational repression (Ni et al., 1995). The full sequence found in Fussenegger et al., 2012 has been retained, as previous analysis has indicated alteration of MS2 coat protein reduces cooperative protein-RNA binding (Uhlenbeck et al., 1995). MS2 is also frequently used in biochemical purification of RNA-protein complexes and is combined with GFP to detect RNA in living cells. <br> </p>
 +
 
 +
<p style="float:none;clear:both; align="center"><center>
 +
<img style="width:70%;" align="middle" src="https://static.igem.org/mediawiki/2014/6/64/Ms2.png" width="500" height="350"></center><br>
 +
</p>
 +
<!--<br> <img class = "floatright" src="https://static.igem.org/mediawiki/2014/6/64/Ms2.png" width="500" height="400" align="left" > </br> -->
 +
 
 +
<br> <p> In the end, we were glad to have used and created two new parts for the iGEM registry - these parts ensure that any system similar to ours can be controlled. Check out the parts pages for more information on both the Aptazyme and the MS2 protein. We were very happy with the responses that we received when giving a SynBioCDT for new and upcoming PhD students - with the general consensus that our system looked both promising and safe. </br> </p>  
 +
 
         </div>
         </div>
         <!--CONTENT END-->
         <!--CONTENT END-->
-
      <!--</div>-->
+
    </div>
   </body>
   </body>

Latest revision as of 02:19, 18 October 2014

Project Specific Changes



As part of the project we looked to spread synthetic biology throughout the community. We approached this feat through several different avenues.



Our project came into fruition after extensive debate and discussion, the idea of introducing a mechanism by which RNA can be propagated is both conceptually and theoretically appealing. Using our replicon system to target production of a siRNA directed against a target (DPP-IV) shows just one of many applications that our system holds. Initially, it was not so straight forward when considering additional elements that we might require – for safety of the system was not on our minds. However, after due deliberation we decided to embark and ask questions and most importantly, seek answers. We started small and simple, with the obvious question on how people perceive our system?

We decided to conduct a Q + A session, in which academics, students and the wider public were in attendance. Whilst lots of interesting questions were raised, we collectively became stuck when faced with the following question:


What have you done to ensure your system is safe?
Having reflected on this question, we realized that we failed to consider how our system would be safe - as one of the main applications of our system was to help treat Diabetes, we had to re-think and go back to the drawing board. We came up with two ideas which we feel will greatly improve the safety, but also the efficiency of our system


Aptazyme
We decided to use a theophylline induced aptazyme, this essentially acts as a kill-switch if our system becomes unstable - it is possible to cleave our siRNA transcript and prevent our system from functioning. A general descriptor for the Aptazyme is below:
An aptazyme is an RNA based switch that operates by ribozyme-mediated cleavage of RNA. This part derives from Hartig et al., 2002 and requires the addition of theophylline to induce hammerhead ribozyme activation and cleavage, as depicted in Figure 1a. The part sequence is modified to contain a stop codon at the end, as an RBS is present.



MS2
In addition, we introduced another safety device, essentially this would rate limit the level of RNA dependent RNA polymerase (RdRp) production. Our design of RNA dependent RNA polymerase essentially incorporated an MS2 bacteriophage coat protein, linked via a P2A linker protein. A general descriptor for the part we used is below: MS2 bacteriophage coat protein part derives from Fussenegger et al., 2012. The MS2 coat protein binds a specific stem-loop structure, referred to as the MS2 box. This acts as a silencing mechanism of RNA through translational repression (Ni et al., 1995). The full sequence found in Fussenegger et al., 2012 has been retained, as previous analysis has indicated alteration of MS2 coat protein reduces cooperative protein-RNA binding (Uhlenbeck et al., 1995). MS2 is also frequently used in biochemical purification of RNA-protein complexes and is combined with GFP to detect RNA in living cells.



In the end, we were glad to have used and created two new parts for the iGEM registry - these parts ensure that any system similar to ours can be controlled. Check out the parts pages for more information on both the Aptazyme and the MS2 protein. We were very happy with the responses that we received when giving a SynBioCDT for new and upcoming PhD students - with the general consensus that our system looked both promising and safe.